Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Ann Hematol ; 100(9): 2375-2380, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34180023

RESUMEN

Damage to gut mucosa following conditioning regimens may favour bacterial infections that can trigger graft versus host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Rifaximin, an oral and non-absorbable antibiotic, has been recently proposed as effective prophylaxis to reduce bacterial infections in the gut and consequently acute GvHD in this setting. The present study evaluated safety and outcomes of HSCT patients that were treated with rifaximin prophylaxis at Perugia University Hospital. Rifaximin prophylaxis was introduced as standard of care in HSCT patients in May 2018. We retrieved data from 118 consecutive transplants, and we compared the outcomes of rifaximin-treated patients with historical controls that did not receive antibiotic prophylaxis. While incidences of neutropenic fever, documented bacterial infections, and aGvHD were similar in the two groups, we found an increased frequency of invasive candidiasis and clinically relevant Candida spp. infections in rifaximin-treated patients (5 patients vs 1 patient, 25% [± 0.99%] vs 1% [± 0.01%], p < .0001). Three rifaximin-treated patients experienced life-threating candidemia (2 C. krusei, 1 C. orthopsilosis). Rifaximin was the only factor that increased the risk of Candida spp. infections. Rifaximin could have contributed to microbiome disruption which favoured an outbreak of life-threatening Candida infections. This important complication forced us to halt its use. Larger, prospective studies are needed to assess the impact of rifaximin prophylaxis on incidence of bacterial infections, aGvHD, and survival of HSCT patients.


Asunto(s)
Antibacterianos/uso terapéutico , Antifúngicos/uso terapéutico , Candida/efectos de los fármacos , Candidiasis/tratamiento farmacológico , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Micafungina/uso terapéutico , Rifaximina/uso terapéutico , Antibacterianos/efectos adversos , Farmacorresistencia Fúngica , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Rifaximina/efectos adversos , Factores de Riesgo , Trasplante Homólogo/efectos adversos
2.
Case Rep Infect Dis ; 2019: 7403878, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31827952

RESUMEN

Histoplasma capsulatum is a dimorphic fungus, endemic in the Americas, Africa (var. duboisii), India, and Southeast Asia. H. capsulatum infection is rarely diagnosed in Italy, while in Latin America, progressive disseminated histoplasmosis (PDH) is one of the most frequent AIDS-defining illnesses and causes of AIDS-related deaths. We report a case of PDH and new HIV infection diagnosis in a Cuban patient, who has been living in Italy for the past 10 years. Bone marrow aspirate and peripheral blood smear microscopy suggested H. capsulatum infection. The diagnosis was confirmed with the culture method identifying its thermal dimorphism. Liposomal amphotericin B was administered alone for 10 days and then for another 2 days, accompanied with voriconazole; the former was stopped for probable side effects (persistent fever and worsening thrombocytopenia), and voriconazole was continued to complete 4 weeks. PDH maintenance treatment consisted of itraconazole for one year. Antiretroviral therapy (ART) was started on the third week of antifungal treatment. At the 3-year follow-up, the patient is adherent on ART, the virus was suppressed, and she has an optimal immune recovery. This case highlights the need to suspect histoplasmosis in the differential diagnosis of opportunistic infections in immunocompromised persons, native to or who have traveled to endemic countries.

3.
Top Curr Chem (Cham) ; 374(1): 5, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27572988

RESUMEN

Despite the large diffusion of natural organic substances in art-historical materials, their characterization presents many challenges due to the chemical complexity and instability with respect to degradation processes. Among natural products, proteins have been largely used in the past as binders but also as adhesives or additives in coating layers. Nevertheless, biological identification of proteins in art-historical objects is one of the most recent achievements obtained in heritage science thanks to the development of specifically tailored bio-analytical strategies. In the context of this active emerging discipline, immunological methods stand out for sensitivity, specificity and versatility for both protein recognition and localization in micro-samples. Furthermore, the growing use of immunological techniques for advanced diagnostics and clinical applications ensures continuous improvement in their analytical performance. Considering such, this review provides an overview of the most recent applications of enzyme linked immunosorbent assay and immunofluorescence microscopy techniques in the field of heritage materials. Specifically, the main strengths and potentials of the two techniques as well as their limits and drawbacks are presented and discussed herein.


Asunto(s)
Ensayo de Inmunoadsorción Enzimática , Microscopía Fluorescente , Proteínas/análisis , Animales , Caseínas/análisis , Humanos , Ovalbúmina/análisis , Proteínas/metabolismo
4.
New Microbiol ; 37(2): 237-40, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24858652

RESUMEN

We describe a case of bloodstream infection caused by a Candida krusei strain that developed echinocandin resistance during caspofungin therapy. Three mutations were found in the HS1 region of the fks1 gene, two of them have never been reported either in C. krusei nor in C. albicans.


Asunto(s)
Antifúngicos/farmacología , Candida/efectos de los fármacos , Candida/enzimología , Candidiasis/microbiología , Equinocandinas/farmacología , Proteínas Fúngicas/genética , Fungemia/microbiología , Glucosiltransferasas/genética , Mutación , Anciano , Sangre/microbiología , Candida/genética , Humanos , Masculino , Pruebas de Sensibilidad Microbiana
5.
Med Mycol Case Rep ; 4: 19-22, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24707460

RESUMEN

Ascending infections of equine uterus frequently result in placentitis and abortions; most of these infections are bacterial and are less commonly due to fungi. This report describes an abortion case in an Arab mare due to Candida guilliermondii that was diagnosed via cytological, histological, cultural and biomolecular assays. The histological lesions found were severe necrotizing placentitis associated with fetal pneumonia. To our knowledge this is the first case of C. guilliermondii abortion reported in equine species.

6.
J Antimicrob Chemother ; 69(4): 1065-74, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24265229

RESUMEN

OBJECTIVES: Micafungin inhibits 1,3-ß-D-glucan synthase and interferes with fungal cell wall synthesis. Clinically, micafungin has been shown to be efficacious for the treatment of invasive fungal infections. However, little is known about the immunomodulatory activity of micafungin in these infections. METHODS: We evaluated the immunomodulatory activity of escalating doses of micafungin in murine and human polymorphonuclear neutrophils (PMNs) in vitro and in vivo in different preclinical models of invasive aspergillosis, including mice deficient for selected innate immune receptors. RESULTS: Micafungin was able to regulate PMN cytokine response to Aspergillus fumigatus conidia by decreasing the expression of tumour necrosis factor-α and increasing that of interleukin-10 (IL-10). In vivo, the therapeutic efficacy of micafungin was strictly dose-dependent, with the maximum activity observed at the highest dose, concomitant with reduced inflammatory pathology. The anti-inflammatory activity of micafungin required IL-10 and occurred through signalling via the TLR2/dectin-1 and TLR3/TRIF pathways. CONCLUSION: Together, these findings suggest that the therapeutic efficacy of micafungin in aspergillosis is orchestrated by the activation of innate immune receptors affecting the inflammatory/anti-inflammatory balance during infection.


Asunto(s)
Aspergilosis/tratamiento farmacológico , Aspergillus fumigatus/efectos de los fármacos , Equinocandinas/uso terapéutico , Factores Inmunológicos/uso terapéutico , Lipopéptidos/uso terapéutico , Animales , Aspergilosis/microbiología , Carga Bacteriana , Células Cultivadas , Equinocandinas/farmacología , Femenino , Histocitoquímica , Humanos , Factores Inmunológicos/farmacología , Lipopéptidos/farmacología , Pulmón/microbiología , Pulmón/patología , Micafungina , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Neutrófilos/efectos de los fármacos , Neutrófilos/microbiología , Resultado del Tratamiento
7.
PLoS Pathog ; 9(7): e1003486, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23853597

RESUMEN

The ability to tolerate Candida albicans, a human commensal of the gastrointestinal tract and vagina, implicates that host defense mechanisms of resistance and tolerance cooperate to limit fungal burden and inflammation at the different body sites. We evaluated resistance and tolerance to the fungus in experimental and human vulvovaginal candidiasis (VVC) as well as in recurrent VVC (RVVC). Resistance and tolerance mechanisms were both activated in murine VVC, involving IL-22 and IL-10-producing regulatory T cells, respectively, with a major contribution by the enzyme indoleamine 2,3-dioxygenase 1 (IDO1). IDO1 was responsible for the production of tolerogenic kynurenines, such that replacement therapy with kynurenines restored immunoprotection to VVC. In humans, two functional genetic variants in IL22 and IDO1 genes were found to be associated with heightened resistance to RVVC, and they correlated with increased local expression of IL-22, IDO1 and kynurenines. Thus, IL-22 and IDO1 are crucial in balancing resistance with tolerance to Candida, their deficiencies are risk factors for RVVC, and targeting tolerance via therapeutic kynurenines may benefit patients with RVVC.


Asunto(s)
Candida albicans/inmunología , Candidiasis Vulvovaginal/inmunología , Tolerancia Inmunológica , Inmunidad Mucosa , Indolamina-Pirrol 2,3,-Dioxigenasa/metabolismo , Interleucinas/biosíntesis , Linfocitos T Reguladores/inmunología , Animales , Candida albicans/efectos de los fármacos , Candida albicans/aislamiento & purificación , Candidiasis Vulvovaginal/genética , Candidiasis Vulvovaginal/metabolismo , Candidiasis Vulvovaginal/microbiología , Femenino , Estudios de Asociación Genética , Variación Genética , Humanos , Tolerancia Inmunológica/efectos de los fármacos , Inmunidad Mucosa/efectos de los fármacos , Factores Inmunológicos/metabolismo , Factores Inmunológicos/uso terapéutico , Indolamina-Pirrol 2,3,-Dioxigenasa/genética , Interleucina-10/biosíntesis , Interleucinas/genética , Quinurenina/metabolismo , Quinurenina/uso terapéutico , Ratones , Ratones Endogámicos C57BL , Ratones SCID , Recurrencia , Inmunodeficiencia Combinada Grave/tratamiento farmacológico , Inmunodeficiencia Combinada Grave/inmunología , Inmunodeficiencia Combinada Grave/fisiopatología , Organismos Libres de Patógenos Específicos , Linfocitos T Reguladores/efectos de los fármacos , Linfocitos T Reguladores/metabolismo , Interleucina-22
8.
Med Mycol ; 51(4): 438-43, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23170963

RESUMEN

A yeast strain was isolated from the sputum sample of a leukaemia patient in the Spirito Santo Hospital of Pescara, Italy. The fungus produced a pigment that formed a reddish halo around colonies, and was identified and deposited as a Metschnikowia spp. (accession number IHEM 25107-GenBank accession number JQ921016) in the BCCM/IHEM collection of biomedical fungi and yeasts (Bruxelles, Belgium). Although the physiology of the strain was close to that of Metschnikowia sinensis, the D1/D2 sequence did not correspond to any previously described Metschnikowia species. Phylogeny of the genus Metschnikowia is complex and requires far more analysis. We present the first non-M. pulcherrima Metschnikowia spp. isolate recovered from a human, and emphasize the role of man as a transient carrier of environmental yeasts, the pathogenicity of which still needs to be defined.


Asunto(s)
Antifúngicos/farmacología , Leucemia/complicaciones , Metschnikowia/aislamiento & purificación , Micosis/microbiología , Pirazinas/metabolismo , Anfotericina B/farmacología , Secuencia de Bases , ADN de Hongos/química , ADN de Hongos/genética , ADN Ribosómico/química , ADN Ribosómico/genética , Fluconazol/farmacología , Humanos , Italia , Masculino , Metschnikowia/clasificación , Metschnikowia/efectos de los fármacos , Metschnikowia/fisiología , Pruebas de Sensibilidad Microbiana , Datos de Secuencia Molecular , Micosis/complicaciones , Filogenia , Pigmentos Biológicos/metabolismo , Análisis de Secuencia de ADN , Esputo/microbiología , Voriconazol/farmacología
9.
Antimicrob Agents Chemother ; 56(8): 4268-76, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22644025

RESUMEN

This study investigated the possible mechanisms underlying the paradoxical caspofungin activity in vivo in preclinical aspergillosis. We evaluated the activity of escalating doses of caspofungin in vivo in different preclinical models of invasive aspergillosis, including mice deficient for selected innate immune receptors. The therapeutic efficacy of caspofungin in experimental invasive aspergillosis was strictly dose dependent, being observed at doses of 0.1 and 1 mg/kg of body weight depending on the experimental models. Paradoxical increase in pulmonary fungal burden as well as inflammatory pathology was observed at the highest dose of caspofungin (5 mg/kg), occurred independently of the so-called Eagle effect and susceptibility to caspofungin in vitro, and was contingent upon the presence of TLR2, Dectin-1, and TLR9. Increased expression of Dectin-1 and TLR9 were observed upon exposure to caspofungin in vitro and in vivo. Together, these findings suggest that the net activity of caspofungin in vivo is orchestrated by the activation, directly or indirectly, of multiple innate immune receptors.


Asunto(s)
Antifúngicos/farmacología , Aspergilosis/tratamiento farmacológico , Equinocandinas/farmacología , Lectinas Tipo C/metabolismo , Enfermedades Pulmonares Fúngicas/tratamiento farmacológico , Receptor Toll-Like 2/metabolismo , Receptor Toll-Like 9/metabolismo , Animales , Antifúngicos/administración & dosificación , Antifúngicos/uso terapéutico , Aspergilosis/inmunología , Aspergilosis/microbiología , Aspergillus fumigatus/efectos de los fármacos , Caspofungina , Equinocandinas/administración & dosificación , Equinocandinas/uso terapéutico , Femenino , Humanos , Lipopéptidos , Pulmón/microbiología , Enfermedades Pulmonares Fúngicas/inmunología , Enfermedades Pulmonares Fúngicas/microbiología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Pruebas de Sensibilidad Microbiana , Receptores Inmunológicos/metabolismo
10.
PLoS One ; 6(11): e28256, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22132241

RESUMEN

In humans, allelic variants in Toll-like receptors (TLRs) associate with several pathologies. However, the underlying cellular and molecular mechanisms of this association remain largely unknown. Analysis of the human TLR9 promoter revealed that the C allele of the rs5743836 polymorphism generates several regulatory sites, including an IL-6-responding element. Here, we show that, in mononuclear cells carrying the TC genotype of rs5743836, IL-6 up-regulates TLR9 expression, leading to exacerbated cellular responses to CpG, including IL-6 production and B-cell proliferation. Our study uncovers a role for the rs5743836 polymorphism in B-cell biology with implications on TLR9-mediated diseases and on the therapeutic usage of TLR9 agonists/antagonists.


Asunto(s)
Alelos , Linfocitos B/citología , Interleucina-6/genética , Polimorfismo de Nucleótido Simple/genética , Regiones Promotoras Genéticas/genética , Receptor Toll-Like 9/genética , Regulación hacia Arriba/genética , Linfocitos B/efectos de los fármacos , Secuencia de Bases , Proliferación Celular/efectos de los fármacos , Genotipo , Humanos , Activación de Linfocitos/efectos de los fármacos , Modelos Biológicos , Datos de Secuencia Molecular , Oligodesoxirribonucleótidos/farmacología , Transcripción Genética/efectos de los fármacos , Regulación hacia Arriba/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA